Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Roivant Sciences Q3 2024 Adj EPS $(0.21) Beats $(0.32) Estimate, Sales $37.14M Beat $32.79M Estimate

Author: Benzinga Newsdesk | February 13, 2024 09:12am
Roivant Sciences (NASDAQ:ROIV) reported quarterly losses of $(0.21) per share which beat the analyst consensus estimate of $(0.32) by 34.38 percent. The company reported quarterly sales of $37.14 million which beat the analyst consensus estimate of $32.79 million by 13.28 percent. This is a 117.80 percent increase over sales of $17.05 million the same period last year.

Posted In: ROIV


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist